Literature DB >> 7842412

Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan.

P G McCulloch1, A Ochiai, G M O'Dowd, J R Nash, M Sasako, S Hirohashi.   

Abstract

BACKGROUND: Differences in the epidemiology and treatment outcome of stomach cancer have led to the suggestion that in Japan, this disease may be biologically less aggressive than that found in the West. The authors compared p53b and c-erb-B2 expression, trying to identify genetic differences in Japanese compared with Western stomach cancers.
METHODS: Paraffin embedded formalin fixed tissues from 89 British and 89 matched Japanese patients were examined by immunohistochemistry after microwave treatment. Cases were matched for T-stage, year of surgery, and histopathologic grade.
RESULTS: Tumors from 48 British and 46 Japanese patients expressed p53, whereas those of 27 British and 28 Japanese patients expressed c-erb-B2. No significant difference in the density or distribution of protein expression was found between the two populations. The distribution of expression between diffuse and intestinal types and the proportion of cases expressing both antigens were similar in the two groups.
CONCLUSIONS: p53 and c-erb-B2 are expressed in the same way in stomach carcinomas from Japanese and British patients. This study found no evidence of genetic differences in the cancers from the two countries.

Entities:  

Mesh:

Year:  1995        PMID: 7842412     DOI: 10.1002/1097-0142(19950215)75:4<920::aid-cncr2820750405>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Gastric cancer.

Authors:  P McCulloch
Journal:  Postgrad Med J       Date:  1996-08       Impact factor: 2.401

Review 2.  Extended lymphadenectomy in gastric cancer: when, for whom and why.

Authors:  D H Roukos
Journal:  Ann R Coll Surg Engl       Date:  1998-01       Impact factor: 1.891

3.  A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.

Authors:  Sung Sook Lee; Hei-Cheul Jeung; Hyun Cheol Chung; Sung Hoon Noh; Woo Jin Hyung; Ji Yeong Ahn; Sun Young Rha
Journal:  Invest New Drugs       Date:  2010-08-24       Impact factor: 3.850

Review 4.  Racial and ethnic disparities in gastric cancer outcomes: more important than surgical technique?

Authors:  Shaila J Merchant; Lily Li; Joseph Kim
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 5.  CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA.

Authors:  Marcelo Garcia Toneto; Luciana Viola
Journal:  Arq Bras Cir Dig       Date:  2018-07-02

6.  Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens.

Authors:  Keisuke Matsusaka; Shumpei Ishikawa; Atsuhito Nakayama; Tetsuo Ushiku; Aiko Nishimoto; Masayuki Urabe; Nobuyuki Kaneko; Akiko Kunita; Atsushi Kaneda; Hiroyuki Aburatani; Mitsuhiro Fujishiro; Yasuyuki Seto; Masashi Fukayama
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

Review 7.  Emerging role of S-1 in gastric cancer.

Authors:  Eriseld Krasniqi; Stefania Pellicori; Vincenzo Formica
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.